Spun off from Merck; sells women's-health drugs, biosimilars, and established off-patent medicines globally.
Spun off from Merck; sells women's-health drugs, biosimilars, and established off-patent medicines globally.
Earns from a few women's health brands, notably the Nexplanon contraceptive implant, and a large group of older medicines whose patents have expired and whose sales slowly erode as generics arrive. Biosimilars, near-copies of biologic drugs, come largely through a partnership with Samsung Bioepis. Spun off from Merck in 2021.
Moat: narrow (brand, distribution). Established global brand recognition helps sustain off-patent products despite generic competition.
Headquarters: Jersey City, New Jersey, US · Founded: 2021 · Employees: 10,000
Size Organon & (OGN) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.66B, the 1397th largest of 3,085 United States companies the cockpit tracks. Shares closed at $13.92 on 18 Nov 2026.
Performance Over six months the shares gained 3.4%, against +3.9% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 19 in its peer set.
Growth Revenue fell 3.2% over the last twelve months (peer median +12.3%); the operating margin is 19.6% (peer median 16.8%).
Valuation It trades at 4.0× forward earnings against a peer median of 20.1× (cheapest of 12).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.7 points above its cost of capital (7.7% WACC).
Credit Organon & has 3 bonds outstanding ($5.07B), rated BB by the agencies and trading like BBB at a weighted spread of 102 bp.
Short interest Short interest is 7.5% of the free float (30 Oct 2026).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $6.10B | $6.22B | $6.40B | $6.26B | $6.17B |
| Revenue growth | — | -3% | +2% | +1% | — |
| Gross profit | $3.27B | $3.36B | $3.71B | $3.75B | $3.89B |
| EBITDA | $1.53B | $1.64B | $1.77B | $1.56B | $1.93B |
| Net income | $213M | $187M | $864M | $1.02B | $917M |
| Free cash flow | $675M | $538M | $764M | $548M | $662M |
| Capital expenditure | $108M | $192M | $246M | $259M | $303M |
| Total debt | $8.55B | $8.80B | $9.04B | $8.93B | $9.11B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Organon & OGN | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 9.9× | -4.3% |
| Viatris VTRS | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.3B | +23% | -4% | 19% | 15.0× | 10.5% |
| Bayer BAYN.DE | $60.3B | +48% | 0% | 13% | 12.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | OGN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.2% | +1.3% | 11th highest of 21 |
| 6-month return | +3.4% | +3.9% | 10th highest of 19 |
| Distance from 52-week high | 0.0% | -24.8% | highest of 21 |
| Revenue growth (TTM) | -3.2% | +12.3% | 5th lowest of 19 |
| Operating margin | 19.6% | 16.8% | 6th highest of 17 |
| Forward P/E | 4.0× | 20.1× | cheapest of 12 |
| Growth the price implies (Req g, 7 yrs) | -4.1% | 3.8% | 3rd least demanding of 13 |
| Growth delivered (Del g) | -1.0% | +9.2% | 2nd lowest of 13 |
| Hurdle (Req g minus delivered) | -3.1 pp | -11.8 pp | 5th most demanding of 13 |
| ROIC minus cost of capital | +3.7 pp | +7.0 pp | 7th lowest of 17 |
| EV / EBITDA | 7.0× | 32.7× | cheapest of 9 |
| Net debt / EBITDA | 4.6× | -0.2× | most indebted of 9 |
| Bond spread | 102 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% | -1.0% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% | +5.9% |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% | +7.8% |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.73B | -9% | -10% | 19% | 11.3× | -7.0% | +2.0% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | n/a | 34.7% | +159.5% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.75B | +12% | +14% | 20% | 21.9× | 1.2% | +12.1% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $3.75B | -10% | -13% | 20% | 28.5× | 16.2% | -5.8% |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | n/a | 58.0% | +4.2% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 16.8× | n/a | n/a |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $3.81B | -38% | +227% | 74% | 39.9× | 0.9% | +45.1% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 63.6× | n/a | n/a |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $3.49B | -38% | +36% | -14% | n/a | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% | +367.3% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% | +12.0% |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | n/a | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% | +10.6% |
| Novast Laboratories 301569.SZ | China | $3.92B | n/a | +3% | 27% | n/a | 57.4% | +3.1% |
Organon & has 3 bonds outstanding with $5.07B face value. The agencies rate it BB; its bonds trade like BBB. Weighted yield 5.16%, a spread of 102 bp over government bonds.